Lung cancer cells can revert identity to a branching state, fueling resistance and aggressive growth
· Medical Xpressedited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Associate Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
trusted source
proofread
The GIST Add as preferred source
Oncologists have discovered that lung cancer cells can change their identity to resist treatment. Research published in Molecular Oncology reveals how lung cancer cells can become more aggressive and harder to treat by reactivating a process involved in early lung development. The paper is titled "Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma."
The findings could help doctors predict which patients are likely to respond to treatment and provide personalized care.
They also open the door to developing new treatments aimed at stopping cancer cells from switching identity.
Researchers at the University of Southampton wanted to understand why some patients don't respond well to current treatments like chemotherapy or immunotherapy.
The team analyzed large datasets from previous cancer study cohorts amounting to samples from over 1,500 patients.
By combining multiple techniques to measure different features across various scales, from individual cells to whole tumor samples, the researchers were able to build a complete picture of the changes associated with disease progression and therapy resistance.
This led to the discovery that a biological process normally activated during the early stages of lung formation was being switched back on, and that this was a key driver of disease progression.
Reawakening early lung development
Dr. Chris Hanley, Associate Professor of Cancer Science at the University of Southampton and senior author on the paper, explains, "Our lungs develop in a similar way to trees, through a branching process in which the trachea divides into two bronchi that repeatedly split into smaller and smaller branches.
"Once the branches are formed, this process is switched off and the body then uses another process to form millions of alveoli—tiny air sacs where oxygen enters the blood—like the leaves at the ends of a tree's branches.
"We've discovered that in some severe lung cancers, cells revert from their alveoli-forming state to their branching state. This helps the cancer to grow, become more aggressive and harder to treat.
"By measuring genes related to branching in samples from patients, we're able to predict how well they might respond to different treatments."
Key molecular switches behind resistance
Further analysis, combined with lab experiments at Southampton's School of Cancer Sciences, revealed some of the underlying molecular regulators behind this process.
The team uncovered the loss of a well-known cancer-protecting gene (TP53) and the activation of a pathway that usually protects against viral infections called interferon signaling.
"In the lab we can see that it's this combination of pathways that drives the change from alveoli forming to branching," says Dr. Hanley.
"While TP53 is known as the 'guardian of the genome,' its role in controlling how cells transition between different states is something that remains poorly understood.
"This new understanding of what is making tumors more aggressive will provide the foundation for further research into targeting these functions, which could lead to new therapies for patients that don't respond well to current treatments."
More information
Kamila J Bienkowska et al, Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma, Molecular Oncology (2026). DOI: 10.1002/1878-0261.70263
Key medical concepts
Adenocarcinoma of LungTP53 protein, humaninterferon-mediated signaling pathway
Clinical categories
OncologyPulmonary medicine Provided by University of Southampton Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Lung cancer cells can revert identity to a branching state, fueling resistance and aggressive growth (2026, May 27) retrieved 27 May 2026 from https://medicalxpress.com/news/2026-05-lung-cancer-cells-revert-identity.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.